Sanofi India, Emcure Pharma forge exclusive partnership for cardiovascular product distribution

Mumbai: In a strategic move, Sanofi India Limited (SIL) has entered into an exclusive agreement with Emcure Pharmaceuticals Limited for the exclusive rights to distribute and promote SIL's range of cardiovascular products across India.

"The Board of Directors of Sanofi India Limited today approved an exclusive distribution and promotion agreement between SIL and Emcure Pharmaceuticals Limited for SIL’s Cardiovascular products in India, effective immediately," the release stated.

Emcure Pharmaceuticals will exclusively distribute and promote the Company’s Cardiovascular (CV) range of products that include well-established brands like Cardace, Clexane, Targocid, Lasix and Lasilactone.

While SIL will continue to own, import, and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all areas of India.

Rodolfo Hrosz Managing Director, Sanofi India Limited said, “Sanofi has been committed to improving lives of patients in India through its range of products. Sanofi India has many cardiovascular products which are leaders in their respective categories. With Emcure’s wide presence across India, our partnership will benefit both HCPs (Healthcare Professionals) and patients by creating the opportunity to maximize the reach of our CV products.”

Read also: Sanofi gets CDSCO Panel nod to study Antidiabetic Drug Insulin Glargine and Lixisenatide Injection

Satish Mehta Chief Executive Officer and Managing Director, Emcure Pharmaceuticals Limited said, “At Emcure Pharmaceuticals our competitive advantage lies in our established presence in all major therapeutic areas including cardiology. We’re delighted to have the opportunity to partner with Sanofi India as their range of well-established cardiovascular brands will complement our strong CV portfolio, making it a highly robust offering. Towards this endeavour, Sanofi’s relevant team also has the opportunity to join us.”

Read also: Sanofi gets CDSCO Panel nod to study Antidiabetic Drug Insulin Glargine and Lixisenatide Injection